UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 923, 2021

GENETHERA, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-27237

65-0622463

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

3051 W 105^th Ave. Westminster, CO		80031
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (720) 587-5100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 1 10.011 GENETHERA, INC. ~~AND~~INCORPORATES ~~CUMMING~~SUBSIDIARY ~~MANAGEMENT~~IN ~~GROUP,~~THE ~~INC.~~UNITED ~~ENTERED INTO A CONSULTING AGREEMENT~~KINGDOM

On April 923, 2021 GeneThera Inc. ~~entered~~received ~~into~~confirmation from aThe ~~consulting~~Registrar ~~agreement~~of ~~with~~Companies ~~Cumming~~for ~~Management~~England ~~Group~~and Wales that GeneThera’s subsidiary, ~~Inc~~GeneThera Robotics Limited., ~~According~~has tobeen registered in the ~~terms~~United on Kingdom. The ownership of the ~~agreement,~~subsidiary ~~Cumming~~is ~~will~~designated ~~provide~~as ~~support~~followed: ~~services~~GeneThera ~~related~~Inc tofifty-one percentage; Alejandra Baglietto forty-nine percentage. On the ~~construction~~same ofday GeneThera’s ~~Biosafety~~Board ~~Level~~of 3Directors ~~(BSL-3) laboratory~~approved ~~facilities~~the toappointment beof ~~used~~Mrs. Alejandra Baglietto as ~~molecular~~Managing Director ~~robotic~~of ~~diagnostic~~GeneThera ~~therapeutic~~Robotics ~~and~~Ltd. ~~research~~GeneThera ~~facilities~~Inc subsidiary will be responsible for ~~SARS-CoV-2~~the UK and ~~other zoonotic~~International ~~diseases.~~operations ~~Scope~~related to the development of the ~~services~~Zoonotic ~~and~~Infectious ~~fees~~Diseases ~~are~~Alert ~~outlined~~Shield in(ZIDAS) ~~Exhibit~~platform. Mrs. Baglietto holds a B.A. and BM.A. ~~attached~~from toCal ~~the~~State ~~Consulting~~University ~~Agreement~~at San Bernardino. ~~GeneThera~~She has worked both in the private and public sector and ~~will~~has ~~proceed~~experience dealing with ~~Cumming~~government asand ~~its~~business ~~sole~~relations, ~~consulting~~clients, ~~services~~communications ~~provider~~and ~~for~~investments. ~~the~~Mrs. ~~related~~Baglietto ~~BSL-3~~has ~~Lab~~worked ~~project~~with numerous private and public companies, most recently, assisting with assessing political risk, international trade investments and ministry of finance guarantees.

Item 9.01 EXHIBITS

Exhibit Number	Description
10.1	Collaboration Agreement

Exhibit Number Description

~~Exhibit~~10.1 AIncorporation Documents

. Exhibit BA

2 Exhibit B

~~SIGNATURES~~ 2

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.SIGNATURES

~~GeneThera,~~Pursuant ~~Inc.,~~to athe ~~Nevada~~requirements ~~Corporation~~of the ~~By:/s/~~Securities ~~Antonio~~Exchange ~~Milici~~Act ~~Antonio~~of ~~Milici~~1934, ~~CEO~~the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

~~Date~~GeneThera, Inc., a Nevada Corporation By: ~~April~~/s/ 27Antonio Milici Antonio Milici, ~~2021~~CEO

3 Date: May 18, 2021

Filing Compare · GENETHERA INC